eligibility_summary
Eligible: advanced cancer expressing GPC3 or mesothelin, life expectancy >12 wks, adequate heart/lung/liver/kidney/blood function, autologous CAR T cells available with ≥20% GPC3/Mesothelin-CAR expression and ≥20% cytotoxicity, informed consent. Exclude: prior gene therapy, HBV/HCV/HIV or active infections, serious comorbidities, pregnancy/lactation, systemic steroids ≥0.5 mg/kg/day, investigator judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: autologous γδT cell therapy and autologous third‑generation CAR‑γδT cells engineered to target glypican‑3 (GPC3) or mesothelin. Type: cell-based gene therapy (engineered T‑cell immunotherapy). Mechanism: baseline γδT cells provide cytotoxicity, CAR engineering adds a synthetic antigen receptor with co‑stimulatory domains that binds GPC3 or mesothelin on tumor cells, triggering T‑cell activation and lysis. Optional PD‑1/PD‑L1/CTLA‑4 antibodies may augment activity. Targets: tumor cells expressing GPC3 or mesothelin (pancreas, lung, liver, mesothelioma). Pathways: CAR signaling, PD‑1/PD‑L1 and CTLA‑4 checkpoints.